Breaking News

Fresenius Kabi Launches Levofloxacin Freeflex IV

August 30, 2013

Designed for easier handling with enhanced safety

Fresenius Kabi USA has launched Levofloxacin in 5% Dextrose Injection in freeflex containers. Freeflex is designed for infusion solutions and has been marketed globally since 2005. Freeflex has multilayer polyolefin film that is PVC-free, plasticizer-free, non-DEHP, and is designed for easier handling with enhanced safety, and environmental performance.
Levofloxacin is a fluoroquinolone antibacterial indicated for use in the treatment of bacterial infections caused by susceptible bacteria, including pneumonia, bronchitis, skin infections, urinary tract infections, prostatitis and anthrax.
“The introduction of Levofloxacin using the freeflex technology expands our market leading anti-infective business with a ready to use formulation and provides customers with a new choice in serving their patients,” said John Ducker, president and chief executive officer of Fresenius Kabi USA.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks